Harvard Bioscience Inc (HBIO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Harvard Bioscience Inc stock (HBIO) is currently trading at $5.13. Harvard Bioscience Inc PS ratio (Price-to-Sales) is 2.73. Analyst consensus price target for HBIO is $6.00. WallStSmart rates HBIO as Sell.
- HBIO PE ratio analysis and historical PE chart
- HBIO PS ratio (Price-to-Sales) history and trend
- HBIO intrinsic value — DCF, Graham Number, EPV models
- HBIO stock price prediction 2025 2026 2027 2028 2029 2030
- HBIO fair value vs current price
- HBIO insider transactions and insider buying
- Is HBIO undervalued or overvalued?
- Harvard Bioscience Inc financial analysis — revenue, earnings, cash flow
- HBIO Piotroski F-Score and Altman Z-Score
- HBIO analyst price target and Smart Rating
Harvard Bioscience Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Harvard Bioscience Inc (HBIO) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Harvard Bioscience Inc (HBIO) Key Strengths (2)
Good growth relative to its price
51.14% held by institutions, strong professional interest
Harvard Bioscience Inc (HBIO) Areas to Watch (8)
Company is destroying shareholder value
Revenue declining -3.30%, a shrinking business
Earnings declining -80.30%, profits shrinking
Company is losing money with a negative profit margin
Very expensive at 16.9x book value
Micro-cap company with very limited liquidity and high volatility
Thin operating margins with cost pressures present
Revenue is fairly priced at 2.73x sales
Harvard Bioscience Inc (HBIO) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 2 register as strengths (avg 8.0/10) while 8 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own.. Valuation metrics including PEG Ratio (1.31) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, EPS Growth. Some valuation metrics including Price/Sales (2.73), Price/Book (16.95) suggest expensive pricing. Growth concerns include Revenue Growth at -3.30%, EPS Growth at -80.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -147.10%, Operating Margin at 14.00%, Profit Margin at -65.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -147.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -3.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HBIO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HBIO's Price-to-Sales ratio of 2.73x trades at a 46% premium to its historical average of 1.87x (88th percentile). The current valuation is 20% below its historical high of 3.4x set in Dec 2006, and 1036% above its historical low of 0.24x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~0.3x, reflecting growing market expectations outpacing revenue growth.
Compare HBIO with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Harvard Bioscience Inc (HBIO) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Harvard Bioscience Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 87M with 330% decline year-over-year. The company is currently unprofitable, posting a -65.5% profit margin.
Key Findings
Revenue contracted 330% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -65.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Harvard Bioscience Inc.
Bottom Line
Harvard Bioscience Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(4 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:27:58 AM
About Harvard Bioscience Inc(HBIO)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.